Haemate

Haemate is an injectable solution containing human coagulation factor VIII and human von Willebrand factor. It is supplied as a prescription‑only product in the European market, with the strength not publicly specified. The formulation is administered intravenously to provide exogenous clotting proteins for patients with deficiencies. Haemate belongs to the class of coagulation factor replacement therapies and is used under medical supervision by qualified healthcare professionals.

Haemate is indicated for the management of bleeding disorders that involve deficiencies of factor VIII and von Willebrand factor.

- Routine prophylaxis to prevent spontaneous bleeding episodes in patients with severe hemophilia A. - On‑demand treatment of acute bleeding episodes in hemophilia A. - Management of bleeding episodes associated with von Willebrand disease types 1, 2, and 3. - Perioperative coverage to maintain hemostasis during surgical or dental procedures in affected individuals. - Adjunct therapy in patients undergoing invasive diagnostics where adequate clotting support is required.

Adverse reactions reported with Haemate reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common: - Mild infusion‑site reactions such as erythema, warmth, or transient pain. - Headache or fatigue occurring shortly after administration. - Low‑grade fever or chills without evidence of infection. - Transient nausea or vomiting during or after infusion.

Serious: - Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension. - Development of inhibitors (neutralizing antibodies) against factor VIII, reducing therapeutic efficacy. - Transmission of infectious agents, although rare, remains a theoretical risk with plasma‑derived products. - Thrombotic events such as deep‑vein thrombosis in patients with pre‑existing risk factors.

When prescribing Haemate, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess patient history for previous allergic reactions to plasma‑derived products. - Screen for existing inhibitors to factor VIII before initiating therapy. - Monitor for signs of infection or febrile reactions during and after infusion. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Adjust dosing in individuals with renal or hepatic impairment as clinically indicated. - Educate patients on proper storage, handling, and disposal of the injectable solution.

Haemate may interact with other medications or biologics that affect hemostasis or immune response.

Avoid: - Concurrent use of other factor concentrates or bypassing agents without specialist guidance. - Administration with investigational gene‑therapy products targeting factor VIII.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability; monitor for excessive thrombosis. - Immunosuppressive drugs can alter inhibitor development risk; coordinate care with hematology. - Vaccines, especially live attenuated, should be timed appropriately around infusion to avoid immune interference.